Leadership Overview
Cambrex has 6 executives leading key functions including strategy, operations, finance, human resources, drug products, and analytical services.
Driven by innovation, Cambrex is a leading global contract development and manufacturing organization providing comprehensive drug lifecycle services, solidifying its position as a trusted partner in both branded and generic pharmaceutical markets.
Driven by innovation, Cambrex is a leading global contract development and manufacturing organization providing comprehensive drug lifecycle services, solidifying its position as a trusted partner in both branded and generic pharmaceutical markets.
Leadership Roles at Cambrex
Thomas Loewald - Chief Executive Officer
Thomas Loewald, the Chief Executive Officer at Cambrex, directs the overarching corporate strategy and operational execution for the global contract development and manufacturing organization. Loewald guides the company's expansion and market positioning, ensuring Cambrex effectively serves clients across the entire drug lifecycle, from development to commercial manufacturing. His leadership focuses on leveraging the company's extensive experience and specialized drug substance technologies, including continuous flow and highly potent APIs, to meet the evolving needs of the pharmaceutical industry. By fostering a culture of innovation and operational excellence, Thomas Loewald drives the company's commitment to being a trusted partner for both branded and generic markets, impacting the delivery of critical medicines worldwide.
Robert Green - Executive VP & Chief Financial Officer
Robert Green, the Executive VP & Chief Financial Officer at Cambrex, manages all financial operations and strategic fiscal planning for the global organization. Green oversees budgeting, forecasting, capital allocation, and investor relations, ensuring the financial health and sustainable growth of Cambrex. His responsibilities include optimizing financial performance, managing risk, and supporting strategic investments in new technologies and expanded capabilities. Robert Green plays a crucial part in the company's long-term financial strategy, aligning fiscal objectives with operational expansion and market development initiatives. This executive leadership ensures Cambrex maintains a strong financial foundation to support its role as a leading CDMO.
Richard Lifsitz - Chief Operating Officer
Richard Lifsitz, the Chief Operating Officer at Cambrex, oversees the day-to-day operational activities and global manufacturing footprint. Lifsitz ensures seamless integration of services across drug substance, drug product, and analytical capabilities, supporting clients from North America and Europe. His focus is on optimizing production processes, enhancing efficiency, and maintaining the highest standards of quality and compliance across all facilities. Richard Lifsitz drives the execution of Cambrex's strategic initiatives, translating corporate goals into tangible operational outcomes that support the reliable supply of APIs and finished dosage forms. This leadership role is critical for scaling operations and meeting the increasing demand for specialized drug development and manufacturing services.
Bruno Biscaro - President, Drug Products
Bruno Biscaro, the President, Drug Products at Cambrex, leads the strategic direction and operational execution for all drug product development and manufacturing services. Biscaro oversees the company's capabilities in conventional and specialized dosage forms, including oral solids, semi-solids, liquids, and advanced forms like modified-release and bi-layer tablets. His focus is on ensuring the seamless delivery of high-quality finished dosage forms to clients, supporting both branded and generic pharmaceutical markets. Bruno Biscaro drives innovation in drug product formulation and manufacturing technologies, ensuring Cambrex remains at the forefront of the industry. This leadership role is essential for translating complex drug substance development into market-ready pharmaceutical products.
Brandon Fincher - President, Analytical Services
Brandon Fincher, the President, Analytical Services at Cambrex, directs the comprehensive analytical testing and characterization capabilities that support the entire drug lifecycle. Fincher oversees a team of experts providing critical services such as material characterization, stability storage, and quality control for both drug substances and drug products. His leadership ensures that Cambrex's analytical services meet rigorous global regulatory standards and provide clients with the precise data needed for development and commercialization. Brandon Fincher drives the advancement of analytical methodologies and technologies, reinforcing Cambrex's position as a trusted partner for API and finished dosage form development. This role is fundamental to guaranteeing product quality and regulatory compliance.
Dottie Brienza - Chief Human Resources Officer
Dottie Brienza, the Chief Human Resources Officer at Cambrex, directs all human capital strategies and organizational development initiatives. Brienza focuses on cultivating a high-performance culture, attracting and retaining top talent, and fostering employee engagement across Cambrex's global operations. Her leadership ensures that the company's growing team of experts is equipped with the necessary resources and development opportunities to support client needs. Dottie Brienza oversees talent acquisition, compensation and benefits, learning and development, and employee relations, all critical functions for a CDMO with over 40 years of experience. This role is vital for maintaining the expertise and dedication required to serve global clients effectively.
Explore Leadership Teams in Manufacturing
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. It markets to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company is headquartered in Parsippany, New Jersey.
Company Leadership KV
KK
RV
About Merz North America Merz North America is a specialty healthcare company dedicated to the development and marketing of innovative quality products for physicians and patients across the United States and Canada. Merz products are distributed through two divisions, Aesthetics and Neurosciences, and are developed with the goal of improving patients health and quality of life by delivering therapies that bring about real progress. Merz North America is a privately-held, family-owned company headquartered in Raleigh, North Carolina. To learn more about Merz North America, please visit www.merzusa.com.
Company Leadership PU
AS
AS
Jubilant Pharmova is a patient-focused biopharmaceutical company based in Noida, India.
Company Leadership VK
SB
AR
HV
Daewoong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both domestic and international markets. With its strong and competent in-house R&D and qualified manufacturing facilities (cGMP), Daewoong provides a total healthcare solution to customers across the globe. Aiming to become a global healthcare company, Daewoong has broadened international operations by establishing branch offices and research centers throughout Asia and the United States. The company was established in 1945 and is headquartered in Seoul, South Korea.
Company Leadership ML
HH
SP
NK
Frequently Asked Questions Regarding Cambrex Top Executives and Leadership Team
